Wyler, S.C. et al. identify a critical neuronal population that is required for GPR75 to exert its obesogenic effects using targeted deletion and reactivation of Gpr75 in glutamatergic neurons.

This Review discusses the expansion of glucagon-like peptide-1 (GLP-1) medicines beyond type 2 diabetes and obesity, outlining opportunities for new indications, key questions around benefits and long...

The authors use Perturb-seq analysis in human pancreatic islet beta cells, as well as in vivo and in vitro analyses, to identify potential therapeutic targets for type 2 diabetes, including ZZEF1, whi...

Scientists are testing whether GLP-1 drugs can help to cut cravings for cigarettes, alcohol and opioids — as well as food.

Biased agonism of the glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptors (GLP-1R/GIPR) yields greater weight loss and bett…

Type 2 diabetes is a polygenic, heterogeneous disease affecting over 530 million individuals worldwide, a number projected to rise to 1.3 billion by 2050. Genome-wide association studies have identifi...

KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera

Our disagreement is not merely political, but a fundamental divide on what it means to live in a society.

Aim To assess whether there is a beneficial or detrimental effect of weight reduction on mental health. Materials and methods Meta-analysis of randomized trials performed for weight loss, in which.....

Susan Stamberg, an original National Public Radio staffer who went on to become the first U.S. woman to anchor a nightly national news program, has died.

What happens when your body suddenly stops making the one hormone that keeps your blood sugar in check?

A new drug slows insulin-dependent diabetic deterioration and has sped up development of a complete remedy

Obesity and its related disorders, including type 2 diabetes and liver, kidney, and cardiovascular diseases, are now recognized as chronic inflammator…

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss. In this Review, the authors discuss the potential effects of GLP-1 receptor agonists on the incidence, disease activity and progression of various forms of arthritis, as well as practical considerations for their use in this context.